Cytokinetics
CYTK
250 hedge funds and large institutions have $3.99B invested in Cytokinetics in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 84 increasing their positions, 79 reducing their positions, and 11 closing their positions.
382% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 11
78% more call options, than puts
Call options by funds: $9.79M | Put options by funds: $5.51M
28% more capital invested
Capital invested by funds: $3.11B → $3.99B (+$879M)
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
18% more funds holding
Funds holding: 211 → 250 (+39)
6% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 79
0.88% more ownership
Funds ownership: 108.08% → 108.97% (+0.88%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$64.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.1M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$25.4M |
| 4 |
RI
RTW Investments
New York
|
+$21.7M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$12.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$28.1M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$26.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$21.7M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$21.7M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$17.9M |
CYTK Hedge Fund Activity: Q4 2021 in Review
250 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2021, worth a combined $3.99B — up 28% from $3.11B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new CYTK positions and 11 closed out — a net gain of 42 holders — while 84 added to existing stakes and 79 trimmed.
The largest buyer was Vanguard Group, adding an estimated $64.6M. The largest seller was Deerfield Management, cutting an estimated $28.1M.
- 250 institutional investors held Cytokinetics (CYTK) as of Q4 2021, up from 211 in Q3 2021.
- Funds reported $3.99B of Cytokinetics stock for Q4 2021, up 28% quarter-over-quarter.
- 53 funds opened new Cytokinetics positions in Q4 2021 and 11 closed out, a net change of +42 holders.
- The largest Cytokinetics buyer in Q4 2021 was Vanguard Group, an estimated $64.6M added.
- The largest Cytokinetics seller in Q4 2021 was Deerfield Management, an estimated $28.1M sold.
Based on aggregated 13F filings for Q4 2021.